Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies, today announced that clinical and preclinical data on the company’s pipeline of candidates will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 7-11, 2018, in Washington, D.C. Ten different abstracts have been selected by the SITC Program Committee attesting to a vigorous and ambitious research program.

Celyad’s pipeline to be highlighted in oral and poster presentations at SITC 2018

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies, today announced that clinical and preclinical data on the company’s pipeline of candidates will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 7-11, 2018, in Washington, D.C. Ten different abstracts have been selected by the SITC Program Committee attesting to a vigorous and ambitious research program.

We view SITC 2018 as an important meeting for a number of reasons”, said David Gilham, Ph.D., VP of Research and Development at Celyad. “Firstly, we will provide a clinical update on our CYAD-01 program in solid tumors. Secondly, we will share how we’ve continued to develop the early academic NKG2D CAR-T asset into the commercially feasible clinical entity CYAD-01. We will provide an update on our next generation CAR-T pipeline, and in particular on our non-gene edited allogeneic CAR-T program. We believe we are on a trajectory to be a leading player in the autologous and allogeneic CAR-T cell therapy landscape in the years to come.

Oral Presentation Details:

Abstract P213:     CYAD-101: an allogeneic NKG2D CAR-T cell therapy using a TCR inhibitory molecule

Date & Time:         November 9, 2 p.m. – 2:05 p.m.

Session:                Rapid Oral Abstracts

 

Poster Details:

Abstract P218:    Endogenous DAP10 provides optimal co-stimulation to NKG2D-based CAR-T cells

Date & Time:         November 10, 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

Session:                Cellular Therapy Approaches

 

Abstract P220:    Generating Allogeneic CAR-T cells without Gene Editing

Date & Time:         November 10, 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

Session:                Cellular Therapy Approaches

 

Abstract P221:    The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR (CYAD-01) generates CAR-T cells resistant to target driven                              fratricide and improves CYAD-01 cell persistence in vivo

Date & Time:         November 9, 12:45 – 2:15 p.m. and 6:30 – 8 p.m.

Session:                Cellular Therapy Approaches

 

Abstract P231:     Uncovering the phenotype, the functional and homing properties of NKG2D CAR-T cells

Date & Time:          November 9, 12:45 – 2:15 p.m. and 6:30 – 8 p.m.

Session:                 Cellular Therapy Approaches

 

Abstract P232:     Differential effects of target ligands upon NKG2D CAR-T cell activation

Date & Time:          November 10, 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

Session:                 Cellular Therapy Approaches

 

Abstract P255:      Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy,                               CYAD-01, in metastatic solid tumors

Date & Time:          November 9, 12:45 – 2:15 p.m. and 6:30 – 8 p.m.

Session:                  Cellular Therapy Approaches

 

Abstract P274:      Functional screening of different anti-B7H6 CAR designs

Date & Time:           November 10, 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

Session:                  Cellular Therapy Approaches

 

Abstract P275:      Pooling signaling and costimulatory domains in a flexible CARpool design

Date & Time:           November 9, 12:45 – 2:15 p.m. and 6:30 – 8 p.m.

Session:                  Cellular Therapy Approaches

 

Abstract P626:       Overcoming target-driven fratricide for CAR-T cell therapy

Date & Time:            November 10, 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m

Session:                   Other

Download press release(s)

Press release

499.96 Ko

Communiqué de presse

225.68 Ko

Persbericht

487.34 Ko

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Nex...

Next News

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Nex...